Eyeworld Daily News

45 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 focus on complex and surgical cases, and the model allowed increased efficiency of patient flow through the practice. Among the challenges of the model was the need for mutual respect and open communication between ophthalmologists and the ODs. "I think all of our physicians would agree that in the right context, and definitely with a foundation of respect between our providers, the MD/OD model of care can be beneficial to all parties," Dr. Sivaraman said. Another opportunity for part- nering with payers is through the Medicare Advantage (MA) program. "The potential for making some serious money is legitimate, and they put a lot of effort into improv- ing their quality performance," Mr. Townsend said. His practice has undertaken several initiatives to help the MA plans with which it is contracted to obtain higher star ratings—the pub- lic-facing quality measurement tool used by Medicare. For instance, his practice provides all of the clinical interpretations of diabetic retinop- athy risk screening exams that MA plans have performed in its area. "We work jointly with the health plan to try to make sure that however many folks there are in that senior plan for whom we are provid- ers that we work with them to try to make sure that those patients get those diabetic retinopathy screens," Mr. Townsend said. His practice also works to bring in patients to a retina specialist within a week if they have positive or problematic screening results. They also partnered with MA plans to perform bilateral cataract surgeries, which provides the same payment to the surgeon that they would have received from 2 sur- geries, but only 1 surgery occurs and half as many postop visits. The arrangement also has the surgery center provide a reduced fee for the health plan. EW Editors' note: Mr. Chambers has financial interests with DCOM Services (Lewisville, Texas). Dr. Sivaraman and Mr. Townsend disclosed no financial interests. down," said Vince Townsend, Albu- querque, New Mexico. Kavitha Sivaraman, MD, Blue Ash, Ohio, described the successful effort of the Cincinnati Eye Institute to utilize an integrated care model with ophthalmologists and optom- etrists. Among the advantages that her organization has found with the integrated model is decreased wait times for patients to see an eyecare provider and access to specialists when referrals are needed. Addi- tionally, physicians were freed to INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3

• Cover